Cargando…

An in-silico evaluation of COVID-19 main protease with clinically approved drugs

A novel strain of coronavirus, namely, SARS-CoV-2 identified in Wuhan city of China in December 2019, continues to spread at a rapid rate worldwide. There are no specific therapies available and investigations regarding the treatment of this disease are still lacking. In order to identify a novel po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tachoua, Wafa, Kabrine, Mohamed, Mushtaq, Mamona, Ul-Haq, Zaheer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Topical Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503128/ https://www.ncbi.nlm.nih.gov/pubmed/33007575 http://dx.doi.org/10.1016/j.jmgm.2020.107758

Ejemplares similares

Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2–P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach
por: Achilonu, Ikechukwu, et al.
Publicado: (2020)

In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus
por: Eleftheriou, Phaedra, et al.
Publicado: (2020)

In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
por: Gurung, Arun Bahadur, et al.
Publicado: (2020)

In Silico Identification and Evaluation of Leads for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease Using Complex Based Pharmacophore Mapping and Virtual Screening
por: Wadood, Abdul, et al.
Publicado: (2014)

Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2
por: Tripathi, Praveen Kumar, et al.
Publicado: (2020)

In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021)

Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach
por: Bello, Martiniano
Publicado: (2020)

Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors
por: Uddin, Reaz, et al.
Publicado: (2022)

MEDT study of the 1,3-DC reaction of diazomethane with Psilostachyin and investigation about the interactions of some pyrazoline derivatives with protease (M(pro)) of nCoV-2
por: Salah, M., et al.
Publicado: (2021)

A combined 3D-QSAR and docking studies for the In-silico prediction of HIV-protease inhibitors
por: Ul-Haq, Zaheer, et al.
Publicado: (2013)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

An open science pathway for drug marketing authorization—Registered drug approval
por: Naudet, Florian, et al.
Publicado: (2021)

Probing CAS database as prospective antiviral agents against SARS-CoV-2 main protease
por: Zia, Komal, et al.
Publicado: (2021)

Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents
por: Ahmed, Mohammad Z., et al.
Publicado: (2021)

Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors
por: Jiménez-Alberto, Alicia, et al.
Publicado: (2020)

Challenges and opportunities for improving access to approved neonatal drugs and devices
por: Lewis, Tamorah, et al.
Publicado: (2022)

Fast Methods for Drug Approval: Research Perspectives for Pandemic Preparedness
por: Abdin, Ahmad Yaman, et al.
Publicado: (2023)

Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease
por: Balakrishnan, Vijayakumar, et al.
Publicado: (2020)

Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
por: Odhar, Hasanain Abdulhameed, et al.
Publicado: (2020)

Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease
por: Elkaeed, Eslam B., et al.
Publicado: (2022)

A Patient‐Centric Model for Discontinuation of a Single‐Sourced Approved Drug
por: Caplan, Arthur, et al.
Publicado: (2019)

Conditional early approval for new drug applications in Japan: Current and emerging issues
por: Tanaka, Mototsugu, et al.
Publicado: (2023)

In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors
por: Ibrahim, Mahmoud A. A., et al.
Publicado: (2021)

A systematic review of cardiac in-silico clinical trials
por: Rodero, Cristobal, et al.
Publicado: (2023)

Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M(pro)) by using STD-NMR spectroscopy, in silico studies and antiviral assays
por: Khan, Abdul Mateen, et al.
Publicado: (2023)

South African experts comment on FDA approval of dabigatran inatrial fibrillation
por: E, Klug, et al.
Publicado: (2011)

In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors
por: Ibrahim, Mahmoud A.A., et al.
Publicado: (2020)

In silico evaluation of the compounds of the ayurvedic drug, AYUSH-64, for the action against the SARS-CoV-2 main protease
por: Ram, Thrigulla Saketh, et al.
Publicado: (2022)

In-silico screening of naturally derived phytochemicals against SARS-CoV Main protease
por: Mostafa, Islam, et al.
Publicado: (2021)

Emergency Medical Services Data for Cardiovascular Disease Surveillance, Program Planning, and Evaluation in Maine
por: Meyer, Katie A, et al.
Publicado: (2008)

Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach
por: Shahabadi, Nahid, et al.
Publicado: (2021)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease
por: OKTAY, Lalehan, et al.
Publicado: (2021)

FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
por: J, Aalbers, et al.
Publicado: (2010)

Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study
por: Ibrahim, Mahmoud A.A., et al.
Publicado: (2021)

In silico evaluation of Philippine Natural Products against SARS-CoV-2 Main Protease
por: Cheng, Adrian Josiah T., et al.
Publicado: (2022)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

Statins and the COVID-19 main protease: in silico evidence on direct interaction
por: Reiner, Željko, et al.
Publicado: (2020)

Identification of correlated inter-residue interactions in protein complex based on the fragment molecular orbital method
por: Tanaka, Shigenori, et al.
Publicado: (2020)

In silico screening, SAR and kinetic studies of naturally occurring flavonoids against SARS CoV-2 main protease
por: Imran, Muhammad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dl106dqog3pmhlpkr4ie1l6r8a